Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17693657 | 0.84 | ALOX15 (0.39) | TSHRALOX15ALOX12LDHA | |
| SCHEMBL7644614 | 0.83 | TP53 (0.46) | TP53TSHRALOX15ALOX12LDHA | |
| SCHEMBL17693635 | 0.78 | TP53 (0.42) | TP53TSHRALOX15ALOX12ELANE | |
| SCHEMBL25395008 | 0.77 | TP53 (0.53) | TP53TSHRALOX15ALOX12 | |
| SCHEMBL29781139 | 0.77 | TP53 (0.53) | TP53TSHRALOX15ALOX12 | |
| SCHEMBL17693594 | 0.73 | ESR1 (0.53) | TP53TSHRALOX15ALOX12 | |
| SCHEMBL5792794 | 0.73 | LDHA (0.58) | TP53TSHRALOX15ALOX12LDHA | |
| SCHEMBL2785384 | 0.73 | TP53 (0.49) | TP53TSHRSMN1; SMN2 | |
| SCHEMBL17693601 | 0.69 | ALDH1A1 (0.48) | TSHR | |
| SCHEMBL16245769 | 0.69 | TSHR (0.44) | TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | ABBVIE INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | ABBVIE INC. | 2016-12-15 | — | — | US | disclosed |
| US-9446059-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885ALOX15 488/4885 |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885ALOX15 488/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885ALOX15 488/4885 |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885ALOX15 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.